VNDA Vanda Pharmaceuticals Inc.

20.8
+0.77  (+4%)
Previous Close 20.03
Open 20.44
Price To Book 4.18
Market Cap 1090957504
Shares 52,449,880
Volume 1,106,339
Short Ratio
Av. Daily Volume 938,946

NewsSee all news

  1. VANDA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals Inc. To Contact The Firm
  2. Lifshitz & Miller LLP Announces Investigation of Bristow Group Inc., Helius Medical Technologies, Inc., Nordstrom Inc., PriceSmart, Inc., Ryanair Holdings plc, Solid Biosciences Inc., and Vanda Pharmaceuticals Inc.
  3. EQUITY ALERT: Rosen Law Firm Continues to Investigate Securities Claims Against Vanda Pharmaceuticals Inc.; Investors are Encouraged to Contact the Firm – VNDA
  4. New Research: Key Drivers of Growth for Arconic, Vanda Pharmaceuticals, Avaya, Sempra Energy, Forward Industries, and Alamo Group — Factors of Influence, Major Initiatives and Sustained Production
  5. Glancy Prongay & Murray LLP Announces Investigation on Behalf of Vanda Pharmaceuticals Inc. Investors

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19615026
  2. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 19613376
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19607919
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19605026
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604922

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2Q 2019.
Tradipitant
Gastroparesis
PK trial initiated with full enrollment completed 4Q 2017.
HETLIOZ (tasimelteon) - pediatric formulation
Insomnia
Approved May 26, 2016.
Fanapt
Supplemental New Drug Application (sNDA) as a maintenance treatment of schizophrenia in adults.
Approved January 31, 2014.
HETLIOZ (tasimelteon)
Insomnia
PDUFA date August 16, 2019.
HETLIOZ (tasimelteon)
Jet Lag Disorder
Phase 3 data released December 10, 2018 - one of two primary endpoints met. sNDA filing due 3Q 2019.
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
Phase 3 data due 1H 2020.
Tradipitant
Atopic dermatitis
Phase 1 initiated October 2018.
VTR-297
Hematologic malignancies
Phase 2 data due 2Q 2019.
Tradipitant
Motion sickness

Latest News

  1. VANDA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals Inc. To Contact The Firm
  2. Lifshitz & Miller LLP Announces Investigation of Bristow Group Inc., Helius Medical Technologies, Inc., Nordstrom Inc., PriceSmart, Inc., Ryanair Holdings plc, Solid Biosciences Inc., and Vanda Pharmaceuticals Inc.
  3. EQUITY ALERT: Rosen Law Firm Continues to Investigate Securities Claims Against Vanda Pharmaceuticals Inc.; Investors are Encouraged to Contact the Firm – VNDA
  4. New Research: Key Drivers of Growth for Arconic, Vanda Pharmaceuticals, Avaya, Sempra Energy, Forward Industries, and Alamo Group — Factors of Influence, Major Initiatives and Sustained Production
  5. Glancy Prongay & Murray LLP Announces Investigation on Behalf of Vanda Pharmaceuticals Inc. Investors
  6. Edited Transcript of VNDA earnings conference call or presentation 13-Feb-19 9:30pm GMT
  7. 3 Top Growth Stocks to Buy Right Now
  8. Here's Why Vanda Pharmaceuticals Gained as Much as 11.1% Today
  9. ONGOING INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  10. The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial
  11. Vanda Pharmaceuticals Inc (VNDA) Q4 2018 Earnings Conference Call Transcript
  12. Vanda Pharmaceuticals (VNDA) Tops Q4 Earnings and Revenue Estimates
  13. INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Vanda Pharmaceuticals Inc. Investors (VNDA)
  14. Vanda: 4Q Earnings Snapshot
  15. Vanda Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results
  16. INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  17. Vanda Pharmaceuticals Inc. to Host Earnings Call

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19615026
  2. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 19613376
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19607919
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19605026
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604922
  6. SC 13G - Statement of acquisition of beneficial ownership by individuals 19600797
  7. 8-K - Current report 19597191
  8. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19582823
  9. 8-K - Current report 19569783
  10. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19555319